Supernus Pharmaceuticals SUPN Other intangible assets—net
Other intangible assets—net at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's other intangible assets—net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's other intangible assets—net?
- Supernus Pharmaceuticals (SUPN) reported other intangible assets—net of $549.71M in Q1 2026.
- How has Supernus Pharmaceuticals's other intangible assets—net changed year-over-year?
- Supernus Pharmaceuticals's other intangible assets—net increased by 9.5% year-over-year, from $502.13M to $549.71M.
- What is the long-term trend for Supernus Pharmaceuticals's other intangible assets—net?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other intangible assets—net has grown at a 9.3% compound annual growth rate (CAGR), from $364.34M to $569.46M.
- What does other intangible assets—net mean?
- This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.